Ascendis Pharma Announces Once-weekly TransCon™ Growth Hormone Demonstrated Superiority on Primary Endpoint Compared to a Daily Growth Hormone in Phase 3 heiGHt Trial for Pediatric Growth Hormone De
Go back to Ascendis Pharma Announces Once-weekly TransCon™ Growth Hormone Demonstrated Superiority on Primary Endpoint Compared to a Daily Growth Hormone in Phase 3 heiGHt Trial for Pediatric Growth Hormone De| Asianada, Inc. (NASDAQ: ASND) | Delayed: 239.31 +1.72 (0.72%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $237.59 | 52 Week High | $21.79 | |||
| Open | $239.09 | 52 Week Low | $11.92 | |||
| Day High | $240.69 | P/E | N/A | |||
| Day Low | $236.00 | EPS | $-0.07 | |||
| Volume | 113,905 | |||||
